What's Happening?
Jeito Capital, a France-based investment group, has successfully closed its second fund, raising €1 billion ($1.2 billion). This marks the largest independent European fund dedicated to biopharma. The Jeito II fund follows the first round, which closed nearly
five years ago with €535 million. The group's assets under management have since tripled to €1.6 billion. Jeito's investments have included successful ventures like EyeBio and HI-Bio, sold for $3 billion and $1.8 billion, respectively. The fund aims to support 15 to 20 clinical-stage biopharma companies, primarily in Europe, with investments up to €150 million each. This development is seen as a positive signal for the European biopharma market, which is rich in scientific talent but lacks long-term growth capital.
Why It's Important?
The closing of Jeito's fund is significant for the European biopharma sector, which is currently facing challenges due to the dominance of U.S. investments and the rise of China as a major player. The fund's success underscores the potential for European companies to drive therapeutic innovation and economic benefits with adequate financial resources. This development could help reverse the trend of declining European shares in global biopharma financing, which has dropped to 15% of the total. By providing substantial capital and strategic resources, Jeito aims to bolster Europe's position in the global biopharma ecosystem.
